Malignant hyperthermia (MH) is an autosomal dominant disorder presenting under general anaesthesia. It is occasionally associated with a myopathy, central core disease (CCD), named after its predominant histochemical characteristic. The penetration of CCD is variable, but typically affected individuals show delayed motor milestones in infancy and remain physically compromised. It was thought until recently that individuals with CCD were always susceptible to MH. Individuals from eight CCD families were screened for the presence of 13 mutations in the skeletal muscle ryanodine receptor gene, reported previously to be associated with MH and/or CCD: none was detected. In seven of these families, where CCD and MH co-existed, we examined the segregation of CCD, MH susceptibility and chromosome 19q markers. In four families, there was complete co-segregation between MH, CCD and the chromosome 19 markers, but in one large pedigree there was a clear lack of segregation of CCD with either MH or chromosome 19 markers and there was no segregation between MH and these markers. This is unequivocal evidence that CCD, in common with MH, is genetically heterogeneous. In the two other families, CCD segregated with chromosome 19 markers but not all individuals with CCD were susceptible to MH. We recommend determination of MH susceptibility in all patients with CCD, irrespective of the MH status of their relatives with CCD. 1999; 83: 217-22 
Susceptibility to malignant hyperthermia (MH) is inherited as an autosomal dominant trait. 1 The condition manifests itself only during general anaesthesia in otherwise healthy susceptible individuals. It is triggered by inhalation anaesthetic agents (e.g. halothane, enflurane, isoflurane, sevoflurane, desflurane), often in conjunction with succinylcholine. Although prompt recognition and appropriate treatment have markedly reduced the mortality rate in recent years, MH remains an important factor in anaestheticinduced morbidity and mortality.
Two reports published in 1990 suggested linkage of a MH locus to chromosome 19q13.1-q13.2. 2 3 McCarthy and colleagues 3 examined three Irish families using several chromosome 19q markers and reported a high probability of linkage. Confirmatory reports of linkage to the same region were published subsequently. [4] [5] [6] One postulated candidate gene in the region is that coding for the skeletal © British Journal of Anaesthesia muscle calcium release channel, the ryanodine receptor gene (RYR1). 2 This proposition was supported by reports that a specific mutation had been found in the homologous gene to RYR1 in pigs that suffer from a similar, but perhaps not identical, disorder to MH. 7 8 Central core disease (CCD) is also a dominantly inherited neuromuscular condition, first described by Shy and Magee, 9 in which individuals have well demarcated, centrally located cores, with a predominance of type 1 muscle fibres. Patients with CCD show wide variation in the severity of their symptoms. The phenotype may include neonatal hypotonia and delay in reaching normal infant motor milestones. 10 Muscle weakness in the lower limbs is another frequently reported complaint, but because the clinical course of CCD is slow or non-progressive, many patients are not diagnosed until later in life.
Patients with CCD are particularly prone to MH crises under general anaesthesia, and it has been assumed widely that CCD and a locus for MH may be allelic (i.e. a single genetic defect is responsible for co-inheritance of CCD and MH). This suggestion has been given further credibility by linkage studies which have localized a CCD locus to chromosome 19 in the region of q13.1, near to RYR1. 11 12 However, we are concerned by a group of UK families in whom MH status and CCD did not apparently coincide 13 and we now report molecular genetic studies on this cohort, in addition to studies conducted on other families.
Patients and methods
Patients were from eight families with a history of MH and/or CCD. In all, 43 individuals from these families had muscle biopsies and in vitro contracture tests on the excised muscle in accordance with European MH group (EMHG) guidelines for the diagnosis of susceptibility to MH. 14 CCD was diagnosed by histological examination of muscle specimens, and DNA analysis was performed on genomic DNA extracted from a venous blood sample obtained when patients attended for muscle biopsy. The pedigrees of all families are shown in Figure 1 . Each family has been allocated a unique identifying code (e.g. LMH 31). Individuals who were tested for and were negative for both CCD and MH are identified by empty symbols, those who were MHN, but had CCD are shown with the top left hand quarter of the symbol filled in, and so on. Clinical details of five of these families (LMH 31, 32, 33, 34 and 38) have been published previously. 13 In pedigree LMH 35, the male proband gave a history of weakness of both the arms and legs which had been present all his life. Some deterioration of symptoms between the ages of 40 and 45 yr led to a diagnosis of CCD by histopathological examination. His non-identical twin brother was not affected, nor was his mother. Of four general anaesthetics administered to this proband, two were reputedly followed by a persistent high temperature. In family LMH 36, the proband was a female born with neuromuscular problems, scoliosis and foot deformities. She was diagnosed originally as having spinal muscular atrophy, but this was confirmed as CCD by histopathology at age 25 yr. She had exhibited mildly progressive weakness of both the arms and legs with muscle wasting. No other family member had any clinical symptoms. In family LMH 37, the proband had a fulminant reaction under general anaesthesia, exhibiting masseter muscle spasm, extreme rigidity, P CO2 9.42 kPa, temperature 40.8°C and a CK concentration of 11856 u. on day 5 after operation. She had no myopathic symptoms. Table 1 provides full diagnostic results for all individuals in all pedigrees, showing the severity of myopathic symptoms, results of in vitro contracture testing, in addition to the percentage of fibres with central cores and the percentage of type 1 fibres found under histological examination.
All patients gave informed consent, and approval for the study was obtained from the Leeds Healthcare/St James's 218 University Hospital NHS Trust Clinical Research (Ethics) Committee.
DNA was obtained from 38 individuals (including II.1 in LMH 35) from the eight families shown in Figure 1 , and this was tested for the presence or absence of the ryanodine receptor gene (RYR1) mutations described in Table 2 . The detection methods used for these mutations are also listed; these involved a PCR of the relevant region of the gene, followed by restriction endonuclease digestion. The name of the restriction endonuclease used in each case is given in italics in Table 2 . In addition, one or two individuals from each family were examined for the presence of the A1565C mutation in RYR1 by direct sequencing of PCR generated products from genomic DNA. 15 Apart from individual II.1 in family LMH 35, all subjects were also typed with the following dinucleotide repeat markers: D19S208, D19S224, D19S421, D19S422, D19S219 16 and D19S112 17 in addition to the tri-nucleotide CTG repeat in the myotonic dystrophy locus. 18 All of these markers flank the RYR1/putative CCD locus on chromosome 19 . Details of all markers are available on the genome database (http://gdbwww.gdb.org/). Primers for each of these markers were labelled with a fluorescent tag and PCR were performed (PCR conditions for the individual markers are available from the corresponding author). Electrophoresis was performed on an ABI 373 genescanner, followed by analysis of the results using 672 and genotyper 1.1r8 software.
Results
There were no mutations in the ryanodine receptor gene in any of the individuals tested. The results of the di-and trinucleotide genotypings are shown in Figure 1 . All markers are shown in the order in which they were located on the chromosome (i.e. from centromere-D19S208, D19S224, D19S421, D19S422, D19S219, CTG in DM, D19S112-to telomere). Haplotypes have been constructed in order to minimize recombinations. Co-segregation of these markers and patient CCD status together with MH phenotype is complete in families LMH 33 and 37 and probably in LMH 38 (it is not possible to define precisely where the recombination event in LMH 38 II:2 has occurred, but it is likely that it is below RYR1). Thus in family LMH 37, all individuals who had CCD were also MHS, and they all shared the same genetic haplotype (1 9 6 9 5 5 9), as indicated by the black haplotype bars under the individual symbols. Whereas in LMH 38, the unaffected individual II:2 had the top portion of the unaffected paternal chromosome (as expected), there was then a recombination event in the area of the candidate gene with the lower part of the haplotype being derived from the affected paternal chromosome.
In family LMH 36, most individuals were fully concordant (i.e. they had the same genetic haplotype) and had both CCD and MHS, or none of those three, but there was one individual who had the susceptible haplotype and was MHS but did not have CCD.
In LMH 31 and 34, CCD co-segregated with the markers on chromosome 19, but unexpectedly all individuals with CCD did not type as MH-positive. In the final family, LMH 32, there was no evidence of linkage between CCD and either diagnosis of MH, or those markers on chromosome 19 which cover the putative candidate region for a CCD gene.
Discussion
Central core disease (CCD) is a relatively uncommon disorder with variable penetrance. Although many of the 220 individuals in this study had delayed motor milestones from birth, others were unaware of their CCD status until after their muscle biopsy results. We have presented molecular genetic analysis on one of the largest described cohorts of CCD patients. It is interesting to note that none of the RYR1 mutations tested for was present in any of the affected or unaffected individuals. This is consistent with the low incidence of these mutations on extensive analysis of MH individuals. 27 Overall, insufficient numbers of CCD patients have been examined, both herein and previously, to accurately document RYR1 sequence variations and establish whether these are a consistent feature of CCD.
As can be seen from the haplotypes displayed in Figure 1 , not only does MH status not always correlate with CCD status but in addition, CCD itself does not always cosegregate with the putative candidate region on chromosome 19. The families described in this article can be separated into three main groups.
Group 1
CCD and MH status co-segregrate with each other and with a common chromosome 19 haplotype (families LMH 33, 37 and 38). These families are consistent with the hypothesis that CCD and MH are allelic and that the gene is (or is very close to) RYR1 on chromosome 19.
Group 2
The CCD phenotype co-segregates with chromosome 19 markers, but not with MH status within the family (LMH 31, 34 and 36). These families illustrate the importance of recommending in vitro contracture testing for all putative CCD cases referred either from a neurologist or after a suspected anaesthetic incident, as clearly not all individuals with CCD have MH. In these pedigrees, CCD and MH could be caused by unrelated defects in different genes. However, given the rarity of the two conditions and a similar occurrence in two pedigrees, a more plausible explanation is that a defect on chromosome 19 leads to CCD, but an additional genetic component is required for the individual to be also MHS. This concept, that MH may not always be monogenic, is supported by other evidence 28 and also by reports of other isolated families with similar results. 29 30 
Group 3
No association is observed between either CCD or MH and the chromosome 19 markers (LMH 32). This last group shows that CCD, in common with MH, is genetically heterogeneous. Genetic linkage of CCD to the candidate region on chromosome 19 is excluded by the presence of at least two recombinant individuals. It will be interesting to discover whether other CCD loci are coincident with any of the other suggested rare MH loci or if they are discrete entities. Unfortunately, the size of LMH 32 does not currently justify a genome search or even specified locus Table 2 Mutations in the skeletal muscle ryanodine receptor gene associated with malignant hyperthermia and/or central core disease, the polymerase chain reaction (PCR) primers and detection method used. Note 1: subjects that proved positive in these digestion tests had their DNA sequenced to determine which particular mutation was present in this region (for example C1840 T or A; C7492T or G7493A). searches to be undertaken with the expectation of significant linkage results. These observations pose inherent problems for the clinical management of patients with CCD with regard to MH status. It would clearly be unwise to assume that if CCD is present in a family it always segregates with MH. We confirm that non-segregation of the CCD phenotype with markers around the RYR1 region on chromosome 19 does occur. 29 30 In one of our families this is definitely the case, and in another it cannot be excluded (LMH 38). This is similar to the degree of heterogeneity found in MH. The size of the non-segregating families is insufficient to enable a reliable genome-wide search for additional loci to be performed, although the insights they provide are invaluable.
In this study, we have not sought to make a distinction between the overlapping conditions of CCD and MH myopathy. 31 Both can be symptomatic of a myopathy or not, and show histological cores and a predominance of type 1 fibres. In the cases we investigated, histology could not be used to distinguish between severely and mildly myopathic individuals because the ranges overlapped. Thus the percentage of fibres with cores ranged from 5-58% in severely myopathic to 27-99% in mildly myopathic individuals, and the percentage of type 1 fibres ranged from 88-100% in severely myopathic to 27-99% in mildly myopathic individuals. Similarly, histology could not be used to distinguish between biopsies from the genetic groups defined here. Percentage of fibres with cores ranged from 0-49% in group 1, 0-96% in group 2, to 1-8% in group 3, while type 1 fibres ranged from 33-100% in group 1, 30-100% in group 2 and 27-60% in group 3.
In summary, it is essential that potential genetic differences between CCD and MH are appreciated to ensure appropriate management of the former group, especially during anaesthesia.
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